Pius Zängerle – Director, curafutura, Switzerland
Pius Zängerle of curafutura, one of the two largest Swiss health insurers’ associations, explains the unique Swiss health insurance ecosystem and the main issues on his agenda for 2021 beyond…
Company Profile
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Switzerland AG
Zählerweg 6
CH 6300 Zug
Switzerland
Phone: +41 41 728 7444
Fax: +41 41 728 7440
www.biogenidec.ch
International Headquarters
Biogen Idec International GmbH
Landis & Gyr-Strasse 3
CH 6300 Zug
Switzerland
Phone: +41 41 39 21700
Fax: +41 41 39 21710
www.biogenidec-international.com
Pius Zängerle of curafutura, one of the two largest Swiss health insurers’ associations, explains the unique Swiss health insurance ecosystem and the main issues on his agenda for 2021 beyond…
A trained physician with several years of practice under her belt, Katharina Gasser then moved into clinical research as an investigator before joining the pharma industry in 2005. Now head…
Alvotech – the biosimilars arm of Icelandic-headquartered generics player Alvogen – is positioning itself for future growth via a very different strategy to that of the Big Pharma players with…
Professor Susan M. Gasser, now director and group leader emeritus of the Friedrich Miescher Institute for Biomedical Research (FMI), shares the crucial aspects behind the FMI’s world-class reputation in basic…
Dr Chris Martin, CEO and co-founder of Swiss-headquartered antibody-drug conjugate cancer company, ADC Therapeutics, shares the company’s journey over the past decade, the exciting progress of their two lead candidates,…
Giorgio Calderari, the chairman of Farma Industria Ticino, the association of chemical and pharmaceutical industries in the Swiss canton of Ticino, explains how a region with a population of 350,000…
The CEO & President of CDMO CordenPharma, Dr Michael Quirmbach, delves into the contract manufacturing industry, explaining the reasons behind the recent commercial success of his organization, including their partnership…
CCO Anil Okay introduces how Alvotech’s focus on biosimilars, comprehensive platform, differentiated portfolio approach, and commercial strategy differentiates the company and allows it to compete with the Big Pharma players…
In an exclusive interview, Jean-Paul Clozel explains Idorsia’s unique value proposition as a biotech focused on small molecules, how agnosticism in terms of therapeutic areas leads to more innovative medical…
AbbVie Switzerland’s Jon Helsdingen outlines how he has led the Swiss affiliate through a full scale office move, the acquisition and integration of Allergan and the COVID-19 pandemic in a…
Mera Pharma’s Khalid Saleh introduces the Swiss-headquartered but MENA-focused company, how it plans to expand via CMOs, and its evolution from food supplements, cosmetics and medical devices into the more…
As part of the Federal Department of Home Affairs, the Federal Office of Public Health (FOPH) is responsible for public health in Switzerland; developing the country’s health policy and working…
See our Cookie Privacy Policy Here
